Interest of the Donor-specific Antibodies After Liver Transplantation

University Hospital, Lille120 enrolled

Overview

The study is a prospective observational mono center study Primary objective : Study the anti-HLA antibodies frequency preformed before liver transplantation and the kinetic of appearance of DSA and de novo complement-binding anti-HLA antibodies after liver transplantation. Secondary objective : * Risk factor of de novo DSA appearance (Immunosuppressive therapy, liver aetiology) * Impact of DSA on: * Graft and patients survivals * Onset of allograft rejection (acute, late-onset, chronic) * Unexplained liver graft dysfunction * Unexplained liver enzymes abnormalities * Liver fibrosis development (liver stiffness study using fibroscan©)

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Liver Transplant

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Liver transplanted patients older than 18, transplanted in Lille University Hospital. * Written consent by the patient or his/her legal representative (especially patient with hepatic encephalopathy). * Patients with health insurance Exclusion Criteria: * Minor patients. * Pregnant women or during lactation. * Patient under curatorship.

Locations (1)

CHRU, Hôpital Claude Huriez

Lille, France

Outcomes

Primary Outcomes

Prevalence DSA positivity (or anti-HLA).

The positivity is defined as a fluorescence ≥ 1000.

Time frame: At baseline

Secondary Outcomes

Fluorescence quantification

Time frame: at 3 months, 1 year and 2 years after transplantation

Presence of C1q binding-complement anti-HLA antibodies

Time frame: at 3 months, 1 year and 2 years after transplantation